FGFR2 and cholangiocarcinoma: The FGFR-specific inhibitors NPV-BGJ398, AZD4547 and JNJ-42756493 are under development for treating lung and breast cancers with FGFR1 amplification, gastric cancer with FGFR2 amplification, cholangiocarcinomas with an FGFR2 fusion, and urothelial cancers with FGFR3 alterations28.